Elon Musk upgrades to 'King Kong' of weight-loss drugs after taking Ozempic as he shares slimmed-down Santa picture at Christmas
Elon Musk, 53, admitted to taking Mounjaro, a drug that typically treats type-2 diabetes by lowering a person's blood sugar ...
Looking at 2025, Health: Breakthroughs of hope and promise
Weight-loss treatments are on the cusp of a revolution, and could benefit large numbers of Indians after the main patent ...
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using a Compounding Pharmacy
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The Herald-Dispatch16h
West Virginians say medications have helped them lose weight, but coverage can be a problem
Mike Plante struggled with his weight for years, but within six months of starting with the injection drug semaglutide, a ...
KSJB AM18h
Which State Medicaid Programs Cover GLP-1s for Weight Loss & How Much Are They Spending?
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...
Tyler Morning Telegraph19h
Medicaid Now Covers GLP-1s for Obesity in Texas
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
The Mountaineer19h
North Carolina Medicaid Spend on GLP-1s for Obesity up 111% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Hastings Tribune19h
Kansas Medicaid Spend on GLP-1s for Obesity up 97% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Hosted on MSN20h
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...